Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Prostate Cancer

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 149 articles:
HTML format



Single Articles


    January 2022
  1. CHAPLOW ZL, Lucas AR, Grainger E, Simpson C, et al
    Social cognitive outcomes are associated with improvements in mobility performance following lifestyle intervention in prostate cancer patients undergoing androgen deprivation therapy.
    PLoS One. 2022;17:e0263136.
    PubMed     Abstract available


  2. NYAMSAMBUU A, Khan MA, Zhou X, Chen HC, et al
    Molecular mechanism of inhibitory effects of melatonin on prostate cancer cell proliferation, migration and invasion.
    PLoS One. 2022;17:e0261341.
    PubMed     Abstract available


  3. KASIVISVANATHAN V, Chan VW, Clement KD, Levis B, et al
    A protocol for the VISION study: An indiVidual patient data meta-analysis of randomised trials comparing MRI-targeted biopsy to standard transrectal ultraSound guided bIopsy in the detection of prOstate cancer.
    PLoS One. 2022;17:e0263345.
    PubMed     Abstract available


  4. SHU W, Tao W, Chunyan H, Jie F, et al
    Preoperative nutritional evaluation of prostate cancer patients undergoing laparoscopic radical prostatectomy.
    PLoS One. 2022;17:e0262630.
    PubMed     Abstract available


  5. LARKIN D, Birtle AJ, Bradley L, Dey P, et al
    A systematic review of disease related stigmatization in patients living with prostate cancer.
    PLoS One. 2022;17:e0261557.
    PubMed     Abstract available


  6. ROGGERO CM, Esser V, Duan L, Rice AM, et al
    Poly-glutamine-dependent self-association as a potential mechanism for regulation of androgen receptor activity.
    PLoS One. 2022;17:e0258876.
    PubMed     Abstract available


  7. FORYS U, Nahshony A, Elishmereni M
    Mathematical model of hormone sensitive prostate cancer treatment using leuprolide: A small step towards personalization.
    PLoS One. 2022;17:e0263648.
    PubMed     Abstract available


  8. SHAO W, Zhang H, Qi H, Zhang Y, et al
    The effects of exercise on body composition of prostate cancer patients receiving androgen deprivation therapy: An update systematic review and meta-analysis.
    PLoS One. 2022;17:e0263918.
    PubMed     Abstract available


  9. ZHANG H, Yang H, Bandyopadhyay S, Milano MT, et al
    Increased risk of high-grade prostate cancer among testicular cancer survivors.
    PLoS One. 2022;17:e0263573.
    PubMed     Abstract available


  10. MARSDEN T, McCartan N, Brown L, Rodriguez-Justo M, et al
    The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses.
    PLoS One. 2022;17:e0259672.
    PubMed     Abstract available


  11. SIEWE N, Friedman A
    Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model.
    PLoS One. 2022;17:e0262453.
    PubMed     Abstract available



  12. Expression of Concern: Akt Mediates Metastasis-Associated Gene 1 (MTA1) Regulating the Expression of E-cadherin and Promoting the Invasiveness of Prostate Cancer Cells.
    PLoS One. 2022;17:e0266930.
    PubMed    


  13. LIN SF, Lin HC, Lee MY, Keller JJ, et al
    Association between GnRH analogue use and atopic diseases in patients with prostate cancer: A population-based retrospective cohort study.
    PLoS One. 2022;17:e0266771.
    PubMed     Abstract available


  14. LEE JJB, Lee E, Choi WH, Kim J, et al
    Dosimetric outcomes of preoperative treatment planning with intraoperative optimization using stranded seeds in prostate brachytherapy.
    PLoS One. 2022;17:e0265143.
    PubMed     Abstract available


  15. TZELVES L, Manolitsis I, Varkarakis I, Ivanovic M, et al
    Artificial intelligence supporting cancer patients across Europe-The ASCAPE project.
    PLoS One. 2022;17:e0265127.
    PubMed     Abstract available


  16. LEE ST, Wong PF, He H, Hooper JD, et al
    Correction: Alpha-Tomatine Attenuation of In Vivo Growth of Subcutaneous and Orthotopic Xenograft Tumors of Human Prostate Carcinoma PC-3 Cells Is Accompanied by Inactivation of Nuclear Factor-Kappa B Signaling.
    PLoS One. 2022;17:e0268234.
    PubMed     Abstract available


  17. WIAFE E, Mensah KB, Oosthuizen F, Bangalee V, et al
    A pilot study of the knowledge, awareness and perception of prostate cancer in Ghanaian women.
    PLoS One. 2022;17:e0267797.
    PubMed     Abstract available


  18. LIN Z, Zhang Z, Ye X, Zhu M, et al
    Based on network pharmacology and molecular docking to predict the mechanism of Huangqi in the treatment of castration-resistant prostate cancer.
    PLoS One. 2022;17:e0263291.
    PubMed     Abstract available



  19. Retraction: Sarcosine Up-Regulates Expression of Genes Involved in Cell Cycle Progression of Metastatic Models of Prostate Cancer.
    PLoS One. 2022;17:e0268981.
    PubMed    


  20. CLARKE CS, Hunter RM, Gabrio A, Brawley CD, et al
    Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
    PLoS One. 2022;17:e0269192.
    PubMed     Abstract available


  21. CHUNG DY, Jung HD, Kim DK, Lee MH, et al
    Outcomes of Retzius-sparing versus conventional robot-assisted radical prostatectomy: A KSER update series systematic review and meta-analysis.
    PLoS One. 2022;17:e0268182.
    PubMed     Abstract available


  22. MOKOATLE M, Mapiye D, Marivate V, Hayes VM, et al
    Discriminatory Gleason grade group signatures of prostate cancer: An application of machine learning methods.
    PLoS One. 2022;17:e0267714.
    PubMed     Abstract available


  23. HARKE NN, Wagner C, Hermann RM, Hadaschik BA, et al
    Lessons learned after one year of COVID-19 from a urologist and radiotherapist view: A German survey on prostate cancer diagnosis and treatment.
    PLoS One. 2022;17:e0269827.
    PubMed     Abstract available


  24. MILOSAVLJEVIC V, Haddad Y, Merlos Rodrigo MA, Moulick A, et al
    Correction: The Zinc-Schiff Base-Novicidin Complex as a Potential Prostate Cancer Therapy.
    PLoS One. 2022;17:e0270734.
    PubMed     Abstract available


  25. LI JR, Wang SS, Chen CS, Cheng CL, et al
    Conventional androgen deprivation therapy is associated with an increased risk of cardiovascular disease in advanced prostate cancer, a nationwide population-based study.
    PLoS One. 2022;17:e0270292.
    PubMed     Abstract available


  26. WANG BJ, Huang SH, Kao CL, Muller CJF, et al
    Aspalathus linearis suppresses cell survival and proliferation of enzalutamide-resistant prostate cancer cells via inhibition of c-Myc and stability of androgen receptor.
    PLoS One. 2022;17:e0270803.
    PubMed     Abstract available


  27. SHAHAIT M, Abu-Hijlih R, Salamat A, Abou Heidar N, et al
    Bone marrow involvement in patients with metastatic castration sensitive prostate cancer.
    PLoS One. 2022;17:e0270956.
    PubMed     Abstract available


  28. ALBERTS I, Butikofer L, Rominger A, Afshar-Oromieh A, et al
    A randomised, prospective and head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT-Protocol design and rationale.
    PLoS One. 2022;17:e0270269.
    PubMed     Abstract available


  29. HENKEL M, Horn T, Leboutte F, Trotsenko P, et al
    Initial experience with AI Pathway Companion: Evaluation of dashboard-enhanced clinical decision making in prostate cancer screening.
    PLoS One. 2022;17:e0271183.
    PubMed     Abstract available


  30. OWOO B, Ninnoni JPK, Ampofo EA, Seidu AA, et al
    "I always find myself very tired and exhausted": The physical impact of caring; a descriptive phenomenological study of the experiences of prostate cancer caregivers in Cape Coast, Ghana.
    PLoS One. 2022;17:e0268627.
    PubMed     Abstract available


    January 2021
  31. QUAGLIA F, Krishn SR, Wang Y, Goodrich DW, et al
    Differential expression of alphaVbeta3 and alphaVbeta6 integrins in prostate cancer progression.
    PLoS One. 2021;16:e0244985.
    PubMed     Abstract available


  32. LABRECQUE MP, Brown LG, Coleman IM, Nguyen HM, et al
    Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.
    PLoS One. 2021;16:e0245602.
    PubMed     Abstract available


  33. OLDE HEUVEL J, de Wit-van der Veen BJ, Sinaasappel M, Slump CH, et al
    Early differences in dynamic uptake of 68Ga-PSMA-11 in primary prostate cancer: A test-retest study.
    PLoS One. 2021;16:e0246394.
    PubMed     Abstract available


  34. GUEST C, Harris R, Sfanos KS, Shrestha E, et al
    Feasibility of integrating canine olfaction with chemical and microbial profiling of urine to detect lethal prostate cancer.
    PLoS One. 2021;16:e0245530.
    PubMed     Abstract available


  35. WANG Y, Wang J, Tang Q, Ren G, et al
    Identification of UBE2C as hub gene in driving prostate cancer by integrated bioinformatics analysis.
    PLoS One. 2021;16:e0247827.
    PubMed     Abstract available


  36. KARLSSON AA, Hao S, Jauhiainen A, Elfstrom KM, et al
    The cost-effectiveness of prostate cancer screening using the Stockholm3 test.
    PLoS One. 2021;16:e0246674.
    PubMed     Abstract available


  37. GRAYSON KA, Jyotsana N, Ortiz-Otero N, King MR, et al
    Overcoming TRAIL-resistance by sensitizing prostate cancer 3D spheroids with taxanes.
    PLoS One. 2021;16:e0246733.
    PubMed     Abstract available


  38. JEONG JU, Nam TK, Song JY, Yoon MS, et al
    Favorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer.
    PLoS One. 2021;16:e0248461.
    PubMed     Abstract available


  39. LIMA CA, da Silva BEB, Hora EC, Lima MS, et al
    Trends in prostate cancer incidence and mortality to monitor control policies in a northeastern Brazilian state.
    PLoS One. 2021;16:e0249009.
    PubMed     Abstract available


  40. ZIAYEE F, Ullrich T, Blondin D, Irmer H, et al
    Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection.
    PLoS One. 2021;16:e0249532.
    PubMed     Abstract available


  41. KHAIRNAR R, Pugh SL, Sandler HM, Lee WR, et al
    Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415.
    PLoS One. 2021;16:e0249123.
    PubMed     Abstract available


  42. CHUNG JW, Kim HT, Ha YS, Lee EH, et al
    Identification of a novel non-invasive biological marker to overcome the shortcomings of PSA in diagnosis and risk stratification for prostate cancer: Initial prospective study of developmental endothelial locus-1 protein.
    PLoS One. 2021;16:e0250254.
    PubMed     Abstract available


  43. ZHANG P, Tan X, Zhang D, Gong Q, et al
    Development and validation of a set of novel and robust 4-lncRNA-based nomogram predicting prostate cancer survival by bioinformatics analysis.
    PLoS One. 2021;16:e0249951.
    PubMed     Abstract available


  44. YADAV MP, Ballal S, Sahoo RK, Tripathi M, et al
    Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
    PLoS One. 2021;16:e0251375.
    PubMed     Abstract available


  45. SAIDOVA AA, Potashnikova DM, Tvorogova AV, Paklina OV, et al
    Myosin 1C isoform A is a novel candidate diagnostic marker for prostate cancer.
    PLoS One. 2021;16:e0251961.
    PubMed     Abstract available



  46. Retraction: Raf Kinase Inhibitor Protein (RKIP) Blocks Signal Transducer and Activator of Transcription 3 (STAT3) Activation in Breast and Prostate Cancer.
    PLoS One. 2021;16:e0253350.
    PubMed    


  47. LOUGHNEY L, McGowan R, O'Malley K, McCaffrey N, et al
    Perceptions of wellbeing and quality of life following participation in a community-based pre-operative exercise programme in men with newly diagnosed prostate cancer: A qualitative pilot study.
    PLoS One. 2021;16:e0253018.
    PubMed     Abstract available


  48. PAROL-KULCZYK M, Gzil A, Maciejewska J, Bodnar M, et al
    Clinicopathological significance of the EMT-related proteins and their interrelationships in prostate cancer. An immunohistochemical study.
    PLoS One. 2021;16:e0253112.
    PubMed     Abstract available


  49. KIM SI, Szeto AH, Morgan KP, Brower B, et al
    A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    PLoS One. 2021;16:e0253021.
    PubMed     Abstract available


  50. GUERRIERO I, Ramberg H, Sagini K, Ramirez-Garrastacho M, et al
    Implication of beta2-adrenergic receptor and miR-196a correlation in neurite outgrowth of LNCaP prostate cancer cells.
    PLoS One. 2021;16:e0253828.
    PubMed     Abstract available


  51. JIANG X, Renkema H, Smeitink J, Beyrath J, et al
    Sonlicromanol's active metabolite KH176m normalizes prostate cancer stem cell mPGES-1 overexpression and inhibits cancer spheroid growth.
    PLoS One. 2021;16:e0254315.
    PubMed     Abstract available


  52. SALMI F, Maachi F, Tazzite A, Aboutaib R, et al
    Next-generation sequencing of BRCA1 and BRCA2 genes in Moroccan prostate cancer patients with positive family history.
    PLoS One. 2021;16:e0254101.
    PubMed     Abstract available


  53. RUNDLE AG, Sadasivan SM, Chitale DA, Gupta NS, et al
    Racial differences in the systemic inflammatory response to prostate cancer.
    PLoS One. 2021;16:e0252951.
    PubMed     Abstract available


  54. ZHANG H, Doucette C, Yang H, Bandyopadhyay S, et al
    Risk of adverse pathological features for intermediate risk prostate cancer: Clinical implications for definitive radiation therapy.
    PLoS One. 2021;16:e0253936.
    PubMed     Abstract available


  55. BARRY DELONGCHAMPS N, Schull A, Anract J, Abecassis JP, et al
    Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial.
    PLoS One. 2021;16:e0252040.
    PubMed     Abstract available


  56. ARIK A, Dodd E, Cairns A, Streftaris G, et al
    Socioeconomic disparities in cancer incidence and mortality in England and the impact of age-at-diagnosis on cancer mortality.
    PLoS One. 2021;16:e0253854.
    PubMed     Abstract available


  57. FALLARA G, Gedeborg R, Bill-Axelson A, Garmo H, et al
    A drug comorbidity index to predict mortality in men with castration resistant prostate cancer.
    PLoS One. 2021;16:e0255239.
    PubMed     Abstract available


  58. CHO D, Milbury K, Liao Y, Pettaway CA, et al
    Study protocol: One plus one can be greater than two-Ecological momentary assessment for Black prostate cancer survivors and partners.
    PLoS One. 2021;16:e0255614.
    PubMed     Abstract available


  59. WEINER F, Schille JT, Hein JI, Wu XF, et al
    Evaluation of combination protocols of the chemotherapeutic agent FX-9 with azacitidine, dichloroacetic acid, doxorubicin or carboplatin on prostate carcinoma cell lines.
    PLoS One. 2021;16:e0256468.
    PubMed     Abstract available


  60. PARK J, Park J, Oh S, Yea JW, et al
    Multi-criteria optimization for planning volumetric-modulated arc therapy for prostate cancer.
    PLoS One. 2021;16:e0257216.
    PubMed     Abstract available


  61. KIM D, Kim DY, Kim JS, Hong SK, et al
    Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy.
    PLoS One. 2021;16:e0256778.
    PubMed     Abstract available


  62. CIMORELLI M, Nieuwland R, Varga Z, van der Pol E, et al
    Standardized procedure to measure the size distribution of extracellular vesicles together with other particles in biofluids with microfluidic resistive pulse sensing.
    PLoS One. 2021;16:e0249603.
    PubMed     Abstract available


  63. TSUZUKI S, Nakanishi S, Tamaki M, Oshiro T, et al
    Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.
    PLoS One. 2021;16:e0258160.
    PubMed     Abstract available


  64. MINAMITANI M, Mukai T, Yamashita H, Katano A, et al
    Effects on annual income changes after radical radiotherapy versus after prostatectomy in patients with localized prostate cancer with a specific employment status: A web-based pilot study.
    PLoS One. 2021;16:e0258116.
    PubMed     Abstract available


  65. HASHIMOTO Y, Shiina M, Maekawa S, Kato T, et al
    Suppressor effect of catechol-O-methyltransferase gene in prostate cancer.
    PLoS One. 2021;16:e0253877.
    PubMed     Abstract available


  66. VETRICHELVAN O, Gorjala P, Goodman O Jr, Mitra R, et al
    Bergamottin a CYP3A inhibitor found in grapefruit juice inhibits prostate cancer cell growth by downregulating androgen receptor signaling and promoting G0/G1 cell cycle block and apoptosis.
    PLoS One. 2021;16:e0257984.
    PubMed     Abstract available


  67. KOGA F, Ito M, Kataoka M, Fukushima H, et al
    Novel anatomical apical dissection utilizing puboprostatic "open-collar" technique: Impact on apical surgical margin and early continence recovery.
    PLoS One. 2021;16:e0249991.
    PubMed     Abstract available


  68. GEDEBORG R, Styrke J, Loeb S, Garmo H, et al
    Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic.
    PLoS One. 2021;16:e0255966.
    PubMed     Abstract available


  69. CHUNG JH, Jeong JY, Lee JY, Song W, et al
    Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value.
    PLoS One. 2021;16:e0249709.
    PubMed     Abstract available


  70. MARKERT L, Holdmann J, Klinger C, Kaufmann M, et al
    Small RNAs as biomarkers to differentiate benign and malign prostate diseases: An alternative for transrectal punch biopsy of the prostate?
    PLoS One. 2021;16:e0247930.
    PubMed     Abstract available


  71. ATHANASIOU A, Tennstedt P, Wittig A, Huber R, et al
    A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology.
    PLoS One. 2021;16:e0259093.
    PubMed     Abstract available


  72. GODTMAN RA, Persson E, Cazzaniga W, Sandin F, et al
    Association of surgeon and hospital volume with short-term outcomes after robot-assisted radical prostatectomy: Nationwide, population-based study.
    PLoS One. 2021;16:e0253081.
    PubMed     Abstract available


  73. CHOI W, Lee H
    Identifying disease-gene associations using a convolutional neural network-based model by embedding a biological knowledge graph with entity descriptions.
    PLoS One. 2021;16:e0258626.
    PubMed     Abstract available


  74. LUO L, Zhang LL, Tao W, Xia TL, et al
    Prediction of potential prognostic biomarkers in metastatic prostate cancer based on a circular RNA-mediated competing endogenous RNA regulatory network.
    PLoS One. 2021;16:e0260983.
    PubMed     Abstract available


  75. KLOSE K, Packeiser EM, Muller P, Granados-Soler JL, et al
    Metformin and sodium dichloroacetate effects on proliferation, apoptosis, and metabolic activity tested alone and in combination in a canine prostate and a bladder cancer cell line.
    PLoS One. 2021;16:e0257403.
    PubMed     Abstract available


  76. KIM SI, Szeto AH, Morgan KP, Brower B, et al
    Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    PLoS One. 2021;16:e0262326.
    PubMed     Abstract available


  77. KIM J, Cho S, Park Y, Lee J, et al
    Evaluation of micro-RNA in extracellular vesicles from blood of patients with prostate cancer.
    PLoS One. 2021;16:e0262017.
    PubMed     Abstract available


    January 2020
  78. JAVAID S, Saad SM, Zafar H, Malik R, et al
    Thymidine phosphorylase and prostrate cancer cell proliferation inhibitory activities of synthetic 4-hydroxybenzohydrazides: In vitro, kinetic, and in silico studies.
    PLoS One. 2020;15:e0227549.
    PubMed     Abstract available


  79. STEINER B, Ferrucci LM, Mirabello L, Lan Q, et al
    Association between coffee drinking and telomere length in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    PLoS One. 2020;15:e0226972.
    PubMed     Abstract available


  80. ULYTE A, Wei W, Dressel H, Gruebner O, et al
    Variation of colorectal, breast and prostate cancer screening activity in Switzerland: Influence of insurance, policy and guidelines.
    PLoS One. 2020;15:e0231409.
    PubMed     Abstract available


  81. DALY C, Logan B, Breeyear J, Whitaker K, et al
    Tks5 SH3 domains exhibit differential effects on invadopodia development.
    PLoS One. 2020;15:e0227855.
    PubMed     Abstract available


  82. HEO JE, Lee JS, Goh HJ, Jang WS, et al
    Urethral realignment with maximal urethral length and bladder neck preservation in robot-assisted radical prostatectomy: Urinary continence recovery.
    PLoS One. 2020;15:e0227744.
    PubMed     Abstract available


  83. MEDHIN LB, Achila OO, Syum BE, Gebremichael KH, et al
    Incidence of prostate cancer in Eritrea: Data from the National Health Laboratory, Orotta Referral Hospital and Sembel Hospital 2011-2018.
    PLoS One. 2020;15:e0232091.
    PubMed     Abstract available


  84. SINGH S, McDonald JT, Ilie G, Adisesh A, et al
    An examination of the association between lifetime history of prostate and pancreatic cancer diagnosis and occupation in a population sample of Canadians.
    PLoS One. 2020;15:e0227622.
    PubMed     Abstract available



  85. Retraction: Prostate Cancer Cell Lines under Hypoxia Exhibit Greater Stem-Like Properties.
    PLoS One. 2020;15:e0233203.
    PubMed    


  86. MURAKAMI Y, Magome T, Matsumoto K, Sato T, et al
    Fully automated dose prediction using generative adversarial networks in prostate cancer patients.
    PLoS One. 2020;15:e0232697.
    PubMed     Abstract available


  87. NGO D, Baumgartner R, Mt-Isa S, Feng D, et al
    Bayesian credible subgroup identification for treatment effectiveness in time-to-event data.
    PLoS One. 2020;15:e0229336.
    PubMed     Abstract available


  88. BRASIL DA COSTA FH, Lewis MS, Truong A, Carson DD, et al
    SULF1 suppresses Wnt3A-driven growth of bone metastatic prostate cancer in perlecan-modified 3D cancer-stroma-macrophage triculture models.
    PLoS One. 2020;15:e0230354.
    PubMed     Abstract available


  89. CHAURASIYA S, Widmann S, Botero C, Lin CY, et al
    Estrogen receptor beta exerts tumor suppressive effects in prostate cancer through repression of androgen receptor activity.
    PLoS One. 2020;15:e0226057.
    PubMed     Abstract available


  90. MACAGNO A, Athanasiou A, Wittig A, Huber R, et al
    Analytical performance of thrombospondin-1 and cathepsin D immunoassays part of a novel CE-IVD marked test as an aid in the diagnosis of prostate cancer.
    PLoS One. 2020;15:e0233442.
    PubMed     Abstract available


  91. GRAHAM LS, Montgomery B, Cheng HH, Yu EY, et al
    Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.
    PLoS One. 2020;15:e0233260.
    PubMed     Abstract available


  92. RIKKERT LG, de Rond L, van Dam A, van Leeuwen TG, et al
    Detection of extracellular vesicles in plasma and urine of prostate cancer patients by flow cytometry and surface plasmon resonance imaging.
    PLoS One. 2020;15:e0233443.
    PubMed     Abstract available


  93. SENNOUNE SR, Nelius T, Jarvis C, Pruitt K, et al
    The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells.
    PLoS One. 2020;15:e0234078.
    PubMed     Abstract available


  94. CHEN MM, Jahn JL, Barber JR, Han M, et al
    Clinical stage provides useful prognostic information even after pathological stage is known for prostate cancer in the PSA era.
    PLoS One. 2020;15:e0234391.
    PubMed     Abstract available


  95. HUSAINI Y, Tsai VW, Manandhar R, Zhang HP, et al
    Growth differentiation factor-15 slows the growth of murine prostate cancer by stimulating tumor immunity.
    PLoS One. 2020;15:e0233846.
    PubMed     Abstract available


  96. SHIN D, Shim SR, Kim CH
    Changes in Beck Depression Inventory scores in prostate cancer patients undergoing androgen deprivation therapy or prostatectomy.
    PLoS One. 2020;15:e0234264.
    PubMed     Abstract available


  97. PACKEISER EM, Hewicker-Trautwein M, Thiemeyer H, Mohr A, et al
    Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis.
    PLoS One. 2020;15:e0230272.
    PubMed     Abstract available


  98. SILTARI A, Murtola TJ, Talala K, Taari K, et al
    Antihypertensive drug use and prostate cancer-specific mortality in Finnish men.
    PLoS One. 2020;15:e0234269.
    PubMed     Abstract available


  99. WU YT, Chiang PH
    Cohort study of high-intensity focused ultrasound in the treatment of localised prostate cancer treatment: Medium-term results from a single centre.
    PLoS One. 2020;15:e0236026.
    PubMed     Abstract available


  100. RHO MJ, Park J, Moon HW, Lee C, et al
    Dr. Answer AI for prostate cancer: Clinical outcome prediction model and service.
    PLoS One. 2020;15:e0236553.
    PubMed     Abstract available


  101. ARIK A, Dodd E, Streftaris G
    Cancer morbidity trends and regional differences in England-A Bayesian analysis.
    PLoS One. 2020;15:e0232844.
    PubMed     Abstract available


  102. DAOUK R, Bahmad HF, Saleh E, Monzer A, et al
    Genome-wide gene expression analysis of a murine model of prostate cancer progression: Deciphering the roles of IL-6 and p38 MAPK as potential therapeutic targets.
    PLoS One. 2020;15:e0237442.
    PubMed     Abstract available


  103. LYNCH SM, Handorf E, Sorice KA, Blackman E, et al
    The effect of neighborhood social environment on prostate cancer development in black and white men at high risk for prostate cancer.
    PLoS One. 2020;15:e0237332.
    PubMed     Abstract available


  104. ERB HHH, Bodenbender J, Handle F, Diehl T, et al
    Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer.
    PLoS One. 2020;15:e0237248.
    PubMed     Abstract available


  105. BOU-DARGHAM MJ, Sang QA
    Secretome analysis reveals upregulated granzyme B in human androgen-repressed prostate cancer cells with mesenchymal and invasive phenotype.
    PLoS One. 2020;15:e0237222.
    PubMed     Abstract available


  106. PAPANDRIANOS N, Papageorgiou E, Anagnostis A, Papageorgiou K, et al
    Bone metastasis classification using whole body images from prostate cancer patients based on convolutional neural networks application.
    PLoS One. 2020;15:e0237213.
    PubMed     Abstract available


  107. YAMADA Y, Teshima T, Fujimura T, Sato Y, et al
    Comparison of perioperative outcomes in elderly (age >== 75 years) vs. younger men undergoing robot-assisted radical prostatectomy.
    PLoS One. 2020;15:e0234113.
    PubMed     Abstract available


  108. SANTOS-SANCHEZ V, Cordoba-Dona JA, Viciana F, Escolar-Pujolar A, et al
    Geographical variations in cancer mortality and social inequalities in southern Spain (Andalusia). 2002-2013.
    PLoS One. 2020;15:e0233397.
    PubMed     Abstract available


  109. STROOMBERG HV, Jorgensen A, Brasso K, Nielsen JE, et al
    Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients.
    PLoS One. 2020;15:e0238814.
    PubMed     Abstract available


  110. GROARKE A, Curtis R, Skelton J, Groarke JM, et al
    Quality of life and adjustment in men with prostate cancer: Interplay of stress, threat and resilience.
    PLoS One. 2020;15:e0239469.
    PubMed     Abstract available


  111. ALADWANI M, Lophatananon A, Robinson F, Rahman A, et al
    Relationship of self-reported body size and shape with risk for prostate cancer: A UK case-control study.
    PLoS One. 2020;15:e0238928.
    PubMed     Abstract available


  112. MISHRA MV, Thayer WM, Janssen E, Hoppe B, et al
    Patient preferences for reducing bowel adverse events following prostate radiotherapy.
    PLoS One. 2020;15:e0235616.
    PubMed     Abstract available


  113. HONG S, Youk T, Lee SJ, Kim KM, et al
    Bone metastasis and skeletal-related events in patients with solid cancer: A Korean nationwide health insurance database study.
    PLoS One. 2020;15:e0234927.
    PubMed     Abstract available


  114. CARLSON AS, Acevedo RI, Lim DM, Gulati R, et al
    Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
    PLoS One. 2020;15:e0239686.
    PubMed     Abstract available


  115. GONCU B, Sevgi E, Kizilarslan Hancer C, Gokay G, et al
    Differential anti-proliferative and apoptotic effects of lichen species on human prostate carcinoma cells.
    PLoS One. 2020;15:e0238303.
    PubMed     Abstract available


  116. YONG C, Moose DL, Bannick N, Gutierrez WR, et al
    Locally invasive, castrate-resistant prostate cancer in a Pten/Trp53 double knockout mouse model of prostate cancer monitored with non-invasive bioluminescent imaging.
    PLoS One. 2020;15:e0232807.
    PubMed     Abstract available


  117. FIORICA PN, Schubert R, Morris JD, Abdul Sami M, et al
    Multi-ethnic transcriptome-wide association study of prostate cancer.
    PLoS One. 2020;15:e0236209.
    PubMed     Abstract available


  118. LI AH, Palmer KS, Taljaard M, Paterson JM, et al
    Effects of quality-based procedure hospital funding reform in Ontario, Canada: An interrupted time series study.
    PLoS One. 2020;15:e0236480.
    PubMed     Abstract available


  119. SANDEMAN K, Eineluoto JT, Pohjonen J, Erickson A, et al
    Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy.
    PLoS One. 2020;15:e0235779.
    PubMed     Abstract available


  120. MEIJER D, Jansen BHE, Wondergem M, Bodar YJL, et al
    Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer.
    PLoS One. 2020;15:e0239414.
    PubMed     Abstract available


  121. SARIISIK E, Zistl D, Docheva D, Schilling AF, et al
    Inadequate tissue mineralization promotes cancer cell attachment.
    PLoS One. 2020;15:e0237116.
    PubMed     Abstract available


  122. SONG Y, Zhang J, Zhang YD, Hou Y, et al
    FeAture Explorer (FAE): A tool for developing and comparing radiomics models.
    PLoS One. 2020;15:e0237587.
    PubMed     Abstract available



  123. Correction: MicroRNA-302a Suppresses Tumor Cell Proliferation by Inhibiting AKT in Prostate Cancer.
    PLoS One. 2020;15:e0241462.
    PubMed     Abstract available


  124. KALINAUSKAITE G, Senger C, Kluge A, Furth C, et al
    68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer.
    PLoS One. 2020;15:e0240892.
    PubMed     Abstract available


  125. KATONGOLE P, Sande OJ, Yusuf M, Joloba M, et al
    Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2015 and 2019 at the Uganda Cancer Institute.
    PLoS One. 2020;15:e0236458.
    PubMed     Abstract available


  126. ZWAANS BMM, Nicolai HE, Chancellor MB, Lamb LE, et al
    Prostate cancer survivors with symptoms of radiation cystitis have elevated fibrotic and vascular proteins in urine.
    PLoS One. 2020;15:e0241388.
    PubMed     Abstract available


  127. BAIO G, Fabbi M, Cilli M, Rosa F, et al
    Manganese-enhanced MRI (MEMRI) in breast and prostate cancers: Preliminary results exploring the potential role of calcium receptors.
    PLoS One. 2020;15:e0224414.
    PubMed     Abstract available


  128. SINGH JP, Dagar M, Dagar G, Kumar S, et al
    Activation of GPR56, a novel adhesion GPCR, is necessary for nuclear androgen receptor signaling in prostate cells.
    PLoS One. 2020;15:e0226056.
    PubMed     Abstract available


  129. HAN C, Yu G, Mao Y, Song S, et al
    LPCAT1 enhances castration resistant prostate cancer progression via increased mRNA synthesis and PAF production.
    PLoS One. 2020;15:e0240801.
    PubMed     Abstract available


  130. NICHOLAS TR, Meng J, Greulich BM, Morris TS, et al
    --A high-throughput screen identifies inhibitors of the interaction between the oncogenic transcription factor ERG and the cofactor EWS.
    PLoS One. 2020;15:e0238999.
    PubMed     Abstract available


  131. TAKAKUSAGI Y, Oike T, Kano K, Anno W, et al
    Prostate-specific antigen dynamics after neoadjuvant androgen-deprivation therapy and carbon ion radiotherapy for prostate cancer.
    PLoS One. 2020;15:e0241636.
    PubMed     Abstract available


  132. MCNABB E, Al-Mahrouki A, Law N, McKay S, et al
    Ultrasound-stimulated microbubble radiation enhancement of tumors: Single-dose and fractionated treatment evaluation.
    PLoS One. 2020;15:e0239456.
    PubMed     Abstract available


  133. HOTKER AM, Bluthgen C, Rupp NJ, Schneider AF, et al
    Comparison of the PI-RADS 2.1 scoring system to PI-RADS 2.0: Impact on diagnostic accuracy and inter-reader agreement.
    PLoS One. 2020;15:e0239975.
    PubMed     Abstract available


  134. CUNNINGHAM J, Thuijsman F, Peeters R, Viossat Y, et al
    Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer.
    PLoS One. 2020;15:e0243386.
    PubMed     Abstract available


  135. FRENDL DM, FitzGerald G, Epstein MM, Allison JJ, et al
    Predicting the 10-year risk of death from other causes in men with localized prostate cancer using patient-reported factors: Development of a tool.
    PLoS One. 2020;15:e0240039.
    PubMed     Abstract available


  136. BRADY L, Hayes B, Sheill G, Baird AM, et al
    Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trial.
    PLoS One. 2020;15:e0243928.
    PubMed     Abstract available


  137. ISHIYAMA Y, Shimbo M, Iizuka J, Deshpande G, et al
    Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort.
    PLoS One. 2020;15:e0244149.
    PubMed     Abstract available


  138. GEDEBORG R, Garmo H, Robinson D, Stattin P, et al
    Prescription-based prediction of baseline mortality risk among older men.
    PLoS One. 2020;15:e0241439.
    PubMed     Abstract available


  139. SHIM M, Bang WJ, Oh CY, Lee YS, et al
    Risk of dementia and Parkinson's disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study.
    PLoS One. 2020;15:e0244660.
    PubMed     Abstract available


  140. GEVAERT T, Van Eycke YR, Vanden Broeck T, Van Poppel H, et al
    The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients.
    PLoS One. 2020;15:e0244663.
    PubMed     Abstract available


  141. GONCU B, Sevgi E, Hancer CK, Gokay G, et al
    Correction: Differential anti-proliferative and apoptotic effects of lichen species on human prostate carcinoma cells.
    PLoS One. 2020;15:e0244831.
    PubMed     Abstract available


  142. KIM HY, Lee DS
    A role for phosphodiesterase type 5 inhibitors in remodelling the urinary bladder after radiation exposure.
    PLoS One. 2020;15:e0242006.
    PubMed     Abstract available


  143. DAHL HC, Kanchwala M, Thomas-Jardin SE, Sandhu A, et al
    Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence.
    PLoS One. 2020;15:e0242970.
    PubMed     Abstract available


  144. FALLARA G, Lissbrant IF, Styrke J, Montorsi F, et al
    Observational study on time on treatment with abiraterone and enzalutamide.
    PLoS One. 2020;15:e0244462.
    PubMed     Abstract available


    January 2019
  145. PAL G, Ogunwobi OO
    Copy number-based quantification assay for non-invasive detection of PVT1-derived transcripts.
    PLoS One. 2019;14:e0226620.
    PubMed     Abstract available


  146. SU SY, Lee WC
    Age-period-cohort analysis with a constant-relative-variation constraint for an apportionment of period and cohort slopes.
    PLoS One. 2019;14:e0226678.
    PubMed     Abstract available


  147. PATEL DI, Abuchowski K, Bedolla R, Rivas P, et al
    Nexrutine and exercise similarly prevent high grade prostate tumors in transgenic mouse model.
    PLoS One. 2019;14:e0226187.
    PubMed     Abstract available


  148. SHARMA D, Giles A, Hashim A, Yip J, et al
    Ultrasound microbubble potentiated enhancement of hyperthermia-effect in tumours.
    PLoS One. 2019;14:e0226475.
    PubMed     Abstract available


  149. BOOTH N, Rissanen P, Tammela TLJ, Kujala P, et al
    Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
    PLoS One. 2019;14:e0224479.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: